PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,314 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock in a transaction on Friday, January 9th. The shares were sold at an average price of $77.93, for a total transaction of $180,330.02. Following the completion of the sale, the vice president directly owned 111,312 shares of the company’s stock, valued at approximately $8,674,544.16. The trade was a 2.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.56, for a total transaction of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total transaction of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.55, for a total transaction of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.99, for a total transaction of $213,683.88.

PTC Therapeutics Stock Performance

Shares of PTCT opened at $77.59 on Tuesday. The firm has a market capitalization of $6.23 billion, a P/E ratio of 9.06 and a beta of 0.49. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50. The stock has a 50 day moving average price of $76.81 and a two-hundred day moving average price of $63.11.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. PTC Therapeutics’s quarterly revenue was up 7.2% on a year-over-year basis. On average, equities analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Wall Street Analyst Weigh In

PTCT has been the subject of several analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $90.00 target price on shares of PTC Therapeutics in a report on Thursday. Royal Bank Of Canada downgraded shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and upped their price objective for the stock from $82.00 to $91.00 in a research report on Monday, December 1st. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, November 5th. Jefferies Financial Group boosted their target price on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, PTC Therapeutics presently has an average rating of “Hold” and an average price target of $77.27.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC provided a detailed update at the J.P. Morgan conference saying Sephience™ (sepiapterin) continues to scale — unaudited Q4 global Sephience revenue of $92.5M, unaudited 2025 total product & royalty revenue of ~ $823M (above guidance), 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth), and cash of ~$1.94B. These results and the 2026 guidance are the main bullish catalysts for the stock today. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Positive Sentiment: PTC presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available), reinforcing commercial execution and management commentary that supports the guidance and growth story. Conference Transcript
• Neutral Sentiment: Reported short interest data shows 0 shares (appears to be a data anomaly / NaN change) and a 0.0 days-to-cover — likely not meaningful to trading given the company’s volume and recent volatility. (Source: market data entry)
• Negative Sentiment: Multiple insiders disclosed open‑market sales between Jan 6–12 (CEO Matthew B. Klein, CFO Pierre Gravier, VP Mark Boulding, EVP/other officers including Eric Pauwels, Christine Utter, Lee Golden, Neil Almstead). Individual sales ranged from several dozen to several thousand shares; the CEO and other executives still retain large positions. Insider selling can create short‑term caution among investors even when shares are sold in open‑market transactions. Key filings/articles: CEO Form 4 (SEC). CEO Form 4 Eric Pauwels Form 4 (SEC). Pauwels Form 4 Media summary of CFO/CEO sales. Insider Selling Article

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in shares of PTC Therapeutics by 587.5% during the 4th quarter. SG Americas Securities LLC now owns 894,461 shares of the biopharmaceutical company’s stock worth $67,943,000 after purchasing an additional 764,364 shares during the last quarter. Diversified Trust Co. lifted its stake in PTC Therapeutics by 4.9% in the fourth quarter. Diversified Trust Co. now owns 17,394 shares of the biopharmaceutical company’s stock valued at $1,321,000 after purchasing an additional 817 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in PTC Therapeutics by 9.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 9,145 shares of the biopharmaceutical company’s stock valued at $701,000 after purchasing an additional 806 shares during the period. GAMMA Investing LLC increased its position in PTC Therapeutics by 160.0% in the fourth quarter. GAMMA Investing LLC now owns 1,451 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 893 shares during the last quarter. Finally, IFP Advisors Inc increased its position in PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 310 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.